Search icon

WELT BIO-MOLECULAR PHARMACEUTICAL, LLC

Company Details

Name: WELT BIO-MOLECULAR PHARMACEUTICAL, LLC
Jurisdiction: New York
Legal type: DOMESTIC LIMITED LIABILITY COMPANY
Status: Active
Date of registration: 14 Nov 2007 (18 years ago)
Entity Number: 3593140
ZIP code: 10504
County: Westchester
Place of Formation: New York
Address: 59 WHIPPOORWILL CROSSING, ARMONK, NY, United States, 10504

DOS Process Agent

Name Role Address
THE LLC DOS Process Agent 59 WHIPPOORWILL CROSSING, ARMONK, NY, United States, 10504

U.S. Small Business Administration Profile

The U.S. Small Business Administration (SBA) helps Americans start, grow, and build resilient businesses.

Note: SBA was created in 1953 as an independent agency of the federal government to aid, counsel, assist and protect the interests of small business concerns; preserve free competitive enterprise; and maintain and strengthen the overall economy of our nation. SBA reviews Congressional and testifies on behalf of small businesses. It assesses the impact of regulatory burden on small businesses.

Phone Number:
E-mail Address:
Fax Number:
914-273-9153
Contact Person:
RACHEL WELT
Ownership and Self-Certifications:
Women-Owned Small Business, Woman Owned
User ID:
P0940250
Trade Name:
WELT BIO-MOLECULAR PHARMACEUTICAL LLC

Unique Entity ID

A UEI is a government-provided number, like a tax ID number, that’s used to identify businesses eligible for federal grants, awards and contracts.

Note: In April 2022, the federal government replaced its old identifier of choice, the Data Universal Numbering System (DUNS) number, with a government-issued UEI. Now all the federal government’s Integrated Award Environment systems use UEI numbers instead of DUNS numbers. So any entity doing business with the federal government must register for a UEI.

Unique Entity ID:
Q9NEYZLBH5G3
CAGE Code:
502Z1
UEI Expiration Date:
2026-04-22

Business Information

Doing Business As:
WELT BIO-MOLECULAR PHARMACEUTICAL LLC
Activation Date:
2025-04-24
Initial Registration Date:
2008-02-25

Commercial and government entity program

The The Commercial And Government Entity Code (CAGE) is assigned by the Department of Defense's Defense Logistics Agency (DLA) and represents your company's physical address for GSA's mailings, payments, and administrative records.

Note: A CAGE Code enables a company to contract with the U.S. government, allowing bid on government contracts and to receive government payments. Also for business this means that it's a Verified business entity and Has a validated physical address.

CAGE number:
502Z1
Status:
Active
Type:
Non-Manufacturer
CAGE Update Date:
2024-05-23
CAGE Expiration:
2029-05-22
SAM Expiration:
2025-05-03

Contact Information

POC:
RACHEL WELT
Phone:
+1 914-400-5309
Fax:
+1 914-273-9153

Filings

Filing Number Date Filed Type Effective Date
191104063028 2019-11-04 BIENNIAL STATEMENT 2019-11-01
171115006164 2017-11-15 BIENNIAL STATEMENT 2017-11-01
151218006050 2015-12-18 BIENNIAL STATEMENT 2015-11-01
131113006397 2013-11-13 BIENNIAL STATEMENT 2013-11-01
111118002606 2011-11-18 BIENNIAL STATEMENT 2011-11-01

USAspending Awards / Financial Assistance

Date:
2023-01-19
Awarding Agency Name:
National Science Foundation
Transaction Description:
SBIR PHASE I: GENERATION OF DIRECTLY ACTIVE MONOCLONAL ANTIBODIES TO CD19 FOR THE TREATMENT OF B-CELL MALIGNANCIES -THE BROADER IMPACT /COMMERCIAL POTENTIAL OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT RELATES TO NOVEL MONOCLONAL ANTIBODY (MAB) THERAPIES FOR THE TREATMENT OF B-CELL CANCERS (LEUKEMIAS AND LYMPHOMAS). CURRENT DRUGS FOR THESE CANCERS CAUSE SEVERE SIDE EFFECTS, AND PATIENTS OVERWHELMINGLY RELAPSE. THE REAGENTS PROPOSED HERE COULD BE THE FIRST MABS TO DIRECTLY INDUCE POTENT THERAPEUTIC EFFECT IN THESE DISEASES AND ARE DESIGNED TO BE MORE TUMOR-SPECIFIC THAN CURRENT THERAPIES. THUS, THE REAGENTS OFFER THE POTENTIAL OF A CURE WHILE MINIMIZING THE LIKELIHOOD OF SIDE EFFECTS. WELL-TOLERATED AND EFFECTIVE THERAPEUTICS ARE A KNOWN UNMET NEED FOR THESE MALIGNANCIES. ADDITIONALLY, THESE DIRECTLY ACTIVE MABS COULD PROVIDE MORE AFFORDABLE OPTIONS THAN THE ENGINEERED ANTIBODIES THAT HAVE RECENTLY BEEN APPROVED. RESEARCH ON THESE MABS WILL ELUCIDATE THE RELATIONSHIP BETWEEN STRUCTURAL ELEMENTS OF RECEPTORS AND THEIR FUNCTION. THE SUCCESS OF THESE MABS WILL VALIDATE A NOVEL DRUG-TARGET DISCOVERY PLATFORM, WHICH WILL BE APPLIED IN DEVELOPING ANTIBODIES TO TREAT OTHER CANCERS AND AUTOIMMUNE DISEASES. THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT APPLIES A DRUG DISCOVERY PLATFORM, FOCUSED ON DEVELOPING MABS TO MEMBRANE RECEPTORS RESPONSIBLE FOR DRIVING ONCOGENIC SIGNALING AND MALIGNANT PHENOTYPES. THESE NOVEL ANTIBODIES MAY INDUCE DIRECT BIOLOGIC EFFECTS BY INTERRUPTING CELL-GROWTH/SURVIVAL PATHWAYS. ONE OF THE KEY PLAYERS IN CONTROLLING MULTIPLE ACTIVATION PATHWAYS INVOLVED IN CELL SURVIVAL AND PROLIFERATION IS CD19, WHICH IS UBIQUITOUSLY EXPRESSED ON B-CELLS AND ITS DYSREGULATION LEADS TO B-CELL MALIGNANCIES. THOUGH CD19 HAS BEEN USED AS A B-CELL-SPECIFIC DRUG TARGET, NO THERAPIES EXIST THAT DIRECTLY IMPACT THE SIGNALING FUNCTION OF THIS RECEPTOR. THIS WORK HAS THE POTENTIAL TO GENERATE MABS TO TWO SELECTED EPITOPES ON CD19. MABS THAT ARE SPECIFIC AND DIRECTLY ACTIVE WILL BE FURTHER DEVELOPED FOR CLINICAL USE. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.
Obligated Amount:
256000.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2010-02-23
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
TARGETING THE B-CELL RECPTOR COMPLEX AND DOWNSTREATM KINASES
Obligated Amount:
127330.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Date of last update: 28 Mar 2025

Sources: New York Secretary of State